PhaseBio Pharmaceuticals, a clinical-stage biopharmaceutical company developing therapies for the treatment of orphan diseases, has entered an exclusive, worldwide license agreement with MedImmune, the global biologics research and development arm of AstraZeneca. The agreement is for PB2452, a Phase 1-ready reversal agent for ticagrelor.   Ticagrelor is unique due to its ability to reversibly bind to the receptor, whereas others like it bind permanently. Due to that fact, ticagrelor is t...